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In this tutorial review, an eﬀort towards presentation of a comprehensive account of the recent
developments on various kinds of artemisinin derivatives including artemisinin dimers, trimers
and tetramers has been made and their eﬃcacy towards malaria parasites and diﬀerent cancer
cells lines was compared with that of artemisinins, and various other anti-malarial and anti-cancer
drugs. It is expected that this review will provide ﬁrst-hand information on artemisinin chemistry
to organic/medicinal chemists, and pharmacologists working on anticancer and anti-malarial drug
development.
1. Introduction
Malaria still remains one of the most dangerous widespread
parasitic diseases of the developing world although it is
known to humankind since ancient times in diﬀerent forms,
and exists over 100 countries, including the United States.1 It
is caused by the Plasmodium parasite and kills approximately
1–3 million people and causes disease in 300–500 million
people annually. The malaria parasite is a Plasmodium
protozoan species, which evolved with time diﬀerentiating into
four distinct species: P. falciparum, P. vivex, P. malarae and
P. ovale, speciﬁc to humans. Some other related species
including P. berghii and P. yeolii are speciﬁc to other groups
of the mammalian class. This disease is transmitted from
person to person through the bite of female anopheles
mosquito. Out of the above four species of the malarial
parasites of human host, Plasmodium vivax, P. malariae and
P. ovale, are the causes of intermittent high fevers making
a person very ill but they are rarely fatal. The remaining species
P. falciparum, is the cause of malignant tertian, falciparum
malaria which has a substantial mortality if it is untreated,
especially in the ﬁrst or an early attack. Among the four human
malaria parasites, P. falciparum has developed resistance to all
of our available drugs, therefore it is an overwhelming cause
of serious disease and death. In patients with severe and
complicated disease, the mortality rate is between 20–50%.
The increasing resistance of malaria parasites to quinoline
based anti-malarial drugs is a major contributor to the
re-emergence of this disease as a major public health problem
and its spread to new locations and populations.
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2. Deﬁned drugs
Commonly used drugs (Fig. 1) in single drug therapy for the
early diagnosed malaria are given below:
(a) Quinine (1): Originally isolated from the bark of the
Cinchona tree, quinine is the only drug which over a long
period of time has remained largely eﬀective in treating the
disease. A number of its derivatives are known to be good
anti-malarials. However, it is now used only for treating severe
falciparum malaria, partly because of undesirable side eﬀects.2
(b) Chloroquine (2): This is eﬀective in curing all forms of
malaria with few side eﬀects when taken in a prescribed dose.
It is still an eﬀective and cheap drug both from prophylactic
and chemotherapeutic point of view. Unfortunately, most strains
of falciparum malaria are now resistant to chloroquine and more
recently resistance of vivax malaria has also been reported.3
(c)Mepacrine (Alebrine) (3): This was developed in the early
1930s and used as a prophylactic on a large scale during the
Second World War (1939–45) and had a major inﬂuence in
reducing the incidence of malaria among the troops serving
Southeast Asia. Because of its many undesirable side eﬀects it
is no longer used in clinics.4
(d) Meﬂoquine (4): Structurally related to quinine it
is eﬀective against many resistant strains of Plasmodium.
Initially it was considered as a good prophylactic because of
its long half life. Widespread resistance and undesirable side
eﬀects (mainly acute brain syndrome) associated with this drug
have resulted in decline of its use.5 Because of its structural
similarity to quinine the two are not recommended together.
(e) Halofantrin (5): This is an eﬀective anti-malarial,
however, due to its short half life of 1 to 2 days and its high
cost, it is not suitable for use as a prophylactic. Unfortunately
resistant forms are increasingly being reported and there is some
concern about its side eﬀects. Halofantrin has been associated
with neuropsychiatric disturbances. It is contra-indicated
during pregnancy and is not advised to women who are
breast-feeding. Abdominal pain, diarrhoea are some of the
common side eﬀects.6
(f) Azithromycin (6): This is a macrocyclic glycosylated
lactone and is mainly used for the chemoprophylaxis. It also
shows limited toxicity but the studies are limited to date.7
(g) Atovaquone (7): This is an important antifolate drug for
malaria treatment and used in combination with proguanil
which is a prodrug and metabolically converted to cycloguanil,
an anti-folate.8
To combat the rapid spread of drug resistant malaria,
eﬀective therapeutic agents are continuously being sought,
especially against those strains which are resistant to
conventional quinoline and acridine based drugs. Wars have
many times led not only to the development of new technology
but also new medicaments. The antimalarial drugs are typical
examples. Chloroquine resulted from the World War II.
Meﬂoquine resulted from the Vietnam War on the American
side. However, what many do not know is that artemisinin
also resulted from the Vietnam War only as a result of large-
scale research launched by the Chinese Government.
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3. Discovery of artemisinin
In 1972, a group of Chinese researchers isolated a new anti-
malarial drug, (+)-artemisinin 8, a sesquiterpene lactone of
the amorphene sub-group of cadinene9 from the hexane
extract of a traditional Chinese medicinal plants, Artemesia
annua (Asteraceae) a plant which has been used for
the treatment of fever and malaria since ancient times.10
Artemisinin is a sesquiterpene lactone containing an endoper-
oxide linkage in it. This highly oxygenated sesquiterpene
lactone peroxide, unlike most other anti-malarials, lacks
nitrogen containing heterocyclic ring systems and was found
to be a superior plasmocidal and blood schizontocidal
agent compared to conventional anti-malarial drugs, such as
chloroquine, quinine etc against malaria strains, without
obvious adverse eﬀects in patients.
Artemisinin is obtained from Artemisia annua in a maximum
yield of 0.1%. This plant is peculiar in its behavior. Carefully
grown plants may be devoid of artemisinin and in order that
the plant synthesizes the product, special agricultural conditions
must be adopted. Best results have been reported in plantations
in North Vietnam, mainly in the vicinity of Hanoi. Highest
content was found about two weeks before ﬂowering.
Artemisinin 8 ($420 kg1) (Fig. 2) is active at nanomolar
concentrations in vitro both against chloroquine sensitive and
resistant P. falciparum strains. However, the practical values
of artemisinin, nevertheless, is impaired by (i) its poor solubility
either in oil or water,11 (ii) the high rate of parasite recrudescence
after treatment12 and (iii) its short-plasma half life (3–5 h) and
its poor oral activity.13 However, a low level of resistance has
recently been observed using artemisinin, which disappeared
as soon as the drug-selection pressure has been withdrawn.
However, artemisinin with an endoperoxide linkage is a
sensitive molecule for large scale derivatization. Fortunately,
it was found that the carbonyl group of artemisinin 8, can
be easily reduced to dihydroartemisinin 9 ($3500 kg1) in
high yields using sodium borohydride, which has in turn led
to the preparation of a series of semi-synthetic ﬁrst-generation
analogues including the oil-soluble artemether 10 and
arteether 11, and water-soluble sodium artesunate 12 and
sodium artelinate 13. These three analogs become very
potent anti-malarial drugs eﬀective against chloroquine-
resistant strains of P. falciparum. Artemether 10 ($3600 kg1),
has been included in the WHO lists of Essential Drugs for the
treatment of severe MDR malaria. In this family, the Walter
Reed Institute of research has patented a stable, water-soluble
derivative called artelinic acid 12 which is now being tested in
animals. A key advantage of these endoperoxides containing
anti-malarial agents, which have been used for nearly two
decades, is the absence of drug resistance.
Although a number of excellent review articles have
been published14 on diﬀerent aspects of artemisinin, we
will concentrate our discussion on the recent and most
important work carried out to study the structure–activity
relationship of artemisinin derivatives which, in recent years
have emerged as a novel class of anti-malarial and anti-cancer
agents.
Fig. 1 Structures of commonly available anti-malarial drugs.
Fig. 2 Structure of artemisinin and its analogs.
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4. Artemisinin derivatives
(A) C-12 ether/ester derivatives
Artemisinin is only sparingly soluble in water or oil and not
well absorbed by the gastro-intestinal tract. Search for more
potent analogues of artemisinin with better bioavailability was
initiated in China focusing attention on ethers and esters
of dihydro-artemisinin i.e. arteether, artemether, artesunate,
artelinate etc. Although these derivatives are potential
antimalarial agents in vitro, they have poor bioavailability,
principally as a result of metabolic instability of the acetal
function.15 One of the principal routes for metabolism of
artemether 10, for example, involves oxidative dealkylation
to give DHA 9, a compound associated with toxicity and short
half life (Scheme 1).
An approach to increasing metabolic stability of artemisinin
derivatives involves incorporation of a phenyl group in place
of alkyl group (in the ether linkage) of arteether and artemether.
This modiﬁcation would be expected to block oxidative
metabolic formation of DHA in vivo. With this idea in mind,
O’Neill’s group synthesized16 a series of C-12 phenoxy
derivatives by reacting DHA with 4 equivalents of the phenol
in anhydrous ether at room temperature in presence of
BF3-etherate. This reaction is believed to proceed via an
oxonium intermediate as shown in Scheme 2.
Several C-12 phenoxy derivatives were evaluated against
malaria parasites and found to possess excellent in vitro
anti-malarial activity. On the basis of the excellent yield and
stereoselectivity obtained from the p-triﬂuoromethyl derivative
15 (R= CF3, IC50 = 3.90 nM), this compound and the parent
phenyl substituted derivative 15 (R = H) were subjected to
in vivo biological evaluation by the authors on P. berghei in a
mouse model and metabolism studies in rats. Compound 15
(R=CF3) demonstrated excellent in vivo antimalarial potency
with an ED50 value of 2.12 mg kg
1 (cf. artemether =
6 mg kg1) vs P. berghei. Furthermore, from preliminary
metabolic studies they have reported that this compound
was not metabolized to dihydroartemisinin, suggesting it
should have a longer half-life and potentially lower toxicity
than arteether and artemether.
As discussed earlier, one of the major disadvantages of using
artemisinins is their poor water solubility. To overcome this
diﬃculty, sugar derivatives of DHA were prepared17 (18a–d)
by condensing 12-O-(trimethylsilyl)dehydroartemisinin 17
with 1-hydroxypolyacetylated sugars in presence of catalytic
amounts of trimethylsilyl triﬂouromethanesulfonate in
CH2Cl2 at 78 1C. Deacetylation of intermediates 18a–d
aﬀorded the desired sugar derivatives 19a–d (Scheme 3). On
in vitro anti-malarial bioassay of the derivatives against
P. falciparum, they were found to be more eﬀective against
W-2 and W-6 clones and were not cross-resistant with existing
anti-malarials.
The trimethylsilyl derivative 17 was more active than
derivatives 18a–d which possess activity comparable to or
better than that of artemisinin 8. However, the deacetylated
compounds 19a–d were substantially less active than the
acetylated ones 18a–d. The anti-malarial activity results
suggested that the in vivo activity of these sugar derivatives
parallel those observed in in vitro tests and that the increase in
polarity or water solubility tends to decrease anti-malarial
activity.
In search of water-soluble and potent artemisinin derivatives,
Li et al. have reported18 syntheses and anti-malarial activities
of new 30 dihydroartemisnin derivatives (Table 1), containing
an amino group (Scheme 4). Syntheses of targeted compounds
were achieved by treatment of dihydroartemisinin 9, with the
allylic alcohol in the presence of BF3Et2O in dry CH2Cl2
solution to furnish compounds 20, 23 in quantitative yield.
Compound 21 was obtained through the epoxidation of 20
using m-chloroperbenzoic acid. A series of amine derivatives
22, 24 were prepared by treating compounds 21 or 23 with
various amines. Treatment of these basic compounds with
organic acids (oxalic acid, maleic acid, etc.) yielded the
corresponding salts. Generally, the maleates have better solubility
in water than the corresponding oxalates. Compounds 24f
(SD50 = 1.61 mg kg
1 day1), 24h (SD50 = 1.74 mg kg
1
day1), and 24r (SD50 = 1.82 mg kg
1 day1) showed 4–5 fold
higher activity against P. berghei infected mice by oral adminis-
tration than artesunic acid 12 (SD50 = 6.33 mg kg
1 day1),
although their activities drastically decrease (30–60 times)
when administered via subcutaneous injection. Compounds
24f, 24h and 24r and artesunic acid 12 in a dose of
3.16 mg kg1 day1 and compounds 24f and 12 in a dose of
10.0 mg kg1 day1 were given orally in P. knowlesi infected
monkeys for 7 days.
Compounds 24f, 24h and 24r reduced parasites more rapidly
than artesunic acid 12, but a dose of 3.16 mg kg1 24f did not
cleanse all parasites. Compounds 24h and 24r recrudescence in
5–10 days after administration, whereas artesunic acid 12 canScheme 1
Scheme 2
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cleanse parasites at a dose of 10.0 or 3.16 mg kg1; no
recrudescence within 105 days was observed. Its contradictory
results in mice and monkeys explain that their water-soluble
artemisinin derivatives have diﬀerent types of absorbtion,
excretion and metabolism in diﬀerent species.
Li et al. found19 that cyano artemether 25, possessed
inhibitory eﬀect against P. falciparum and no cytotoxic eﬀect
against P388 cells in vitro, and that a pair of isomers
(compound 26a and 27a) in test of antiproliferative potential
displayed in vitro cytotoxicity against P388 and L1210 murine
leukemia cell lines. They prepared the compound 26b (22%
yield) and 27b (25% yield), as a pair of isomers, in the presence
of BF3Et2O with 2-(4-bromophenyl)-2-hydroxyacetonitrile
and KCN. These compounds were tested for the anti-
proliferative eﬀect against P388 and A549 tumor cell lines
(Scheme 5). In order to test whether the peroxy group is
essential for anti-tumor activity, compound 28 (60% yield)
was also prepared from compound 27b. Compound 26b and
27b showed the potent and similar activity to inhibit the
proliferation of P388 and A549 cells, but compound 28 was
not active. It is noteworthy that the peroxy group appears to
be essential for cytotoxicity as in the case of anti-malarial
activity, and the conﬁguration of C-16 has insigniﬁcant inﬂuence
on the activity. Compounds 26b and 27b were equipotent for
the inhibition of the proliferation and cell cycle progression.
The immunosuppressive action of artemisinin and its
derivatives has also been studied in China for many years.
Many experimental results in vitro and in vivo suggested that
these new type of antimalarial drugs, such as artemisinin 8,
dihydroartimisinin 9, artemether 10, and artesunic acid 12,
Scheme 3
Scheme 4
Table 1 Series of synthesized compounds
n NR1R2 n NR1R2 n NR1R2 n NR1R2
24aa 2 NHMe 24ha 2 NEt2 24v
b 2 C 24ob 3 NH(CH2)3NMe2
24bb 2 NHMe 24ib 2 NEt2 24p
b 2 A 24wb 2 D
24cb 2 NHEt 24jb 3 NEt2 24q
b 2 A 22ab NMe2
24da 2 NH(n-C3H7) 24k
b 2 NH(CH2)2OH 24r
b 3 A 22bb NEt2
24eb 2 NH(i-C3H7) 24l
b 2 NH(CH2)2NMe2 24s
c 3 A 22cb NH(i-C3H7)
24fa 2 NMe2 24m
b 2 NH(CH2)2NMe2 24t
a 2 B 22db A
24gb 2 NMe2 24n
b 2 NH(CH2)2CN 24u
b 2 B 22eb E
HNR1R2 = morpholine (A), piperazine (B), N-methylpiperazine (C), N-diphenylmethylpiperazine (D), pyrrolidine (E).
a As oxalate salt.
b As maleate salt. c As fumerate salt.
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possessed deﬁnite immunosuppressive activity.20 In search for
new potential immunosuppressive agents with much higher
eﬃcacy and lower toxicity, Yang et al. have synthesized21 a
class of novel artemisinin derivatives (30–37) starting from
dihyroartemisinin acetate 29 (Scheme 6) and found that
introduction of phen(oxy)yl aliphatic acid and ester into
artemisinin nucleus enhanced their immunosuppressive activity.
These compounds (30–37) were assayed in their cytotoxicity of
lymphocyte, inhibition activity on cancanavalin A (ConA)
induced T cell proliferation and lipopolysaccharide (LPS)
induced B cell proliferation. Among them, 31b, 33b, 34d,
35b, 36, and 37 remarkably exhibited lower cytotoxicity and
higher inhibition activity on the mitogen-induced T-cell and
B-cell proliferation in comparison with artemisinin, artesunate,
and artemether in vitro. More signiﬁcantly, compound
31b-displayed reduced cytotoxicity by over 100-fold compared
with cyclosporine A (CsA) and comparable inhibition
activity (SI = 848) on ConA-induced T cell proliferation to
CsA (SI = 963) and more than 4000 times the inhibitory eﬀect
(SI = 28473) on LPS-induced B-cell proliferation compared
with CsA (SI = 7) in vitro. The in vivo experimental results
showed that compound 36 could inhibit 2,4-dinitroﬂuorobenzene
(DNFB)-induced delayed type hypersensitivity (DTH) reaction
and sheep red blood cells (SRBC) induced antibody, production
respectively.
Based on their previous work, Yang et al. have further
extended the study of immunosuppressive activity of a new
series of substituted phenoxy propionic acids and ester
derivatives (38,39).22 The synthesis of targeted compounds
were achieved using dihydroartemisinin 9 (Scheme 7). These
new dihydroartemisinin derivatives were tested in vitro for
their cytotoxicity on murine spleen cells and inhibitory activity
on ConA-induced T cell proliferation or lipopolysaccharide
(LPS) induced B cell proliferation with artemisinin, artemether,
and artesunate as the controls. The cytotoxicity of each
compound was expressed as the concentration of compound
that reduced cell viability to 50% (CC50). The immuno-
suppressive activity of each compound was expressed as the
concentration of compound that inhibited ConA-induced T
cell proliferation and LPS-induced B cell proliferation to 50%
(IC50) of the control value. Among the whole series of
compounds, 38a (IC50 = 6.8  107), 38e (IC50 = 4.6 
107), 38h (IC50 = 7.0  107), and 38j (IC50 = 8.4  107)
had 5- to 9-fold higher bioactivity than artemisinin (IC50 =
4.4  106), artemether (IC50 = 3.8  106), artesunate
(IC50 = 4.8  106) in the ConA-induced T cell proliferation.
In the inhibition of LPS-induced B cell proliferation 38e (IC50 =
2.8  107), 38f (IC50 = 1.6  107), 38g (IC50 = 3.0  107),
38j (IC50 = 2.2  107), 39a (IC50 = 5.0  107), 39b
(IC50 = 1.8  107), 39c (IC50 = 1.0  107), and 39e
(IC50 = 1.7 107), exhibited 30- to 88-fold higher bioactivity
than artemisinin (IC50 = 9.0  106), artemether (IC50 =
1.8  106), and artesunate (IC50 = 9.9  107) respectively.
Yang et al. have also synthesized23 a series of artemisinin
derivatives bearing Mannich base groups (40a and 40b) starting
from dihydroartemisinin 9 and tested for their anti-malarial
activity against P. berghei and P. falciparum in K1 and NF54
cells. Compound 40a (IC50 = 0.18 and 0.36 ng mL
1) and 40b
(IC50 = 0.25 and 0.17 ng mL
1) were found to be more
active in mice than artesunic acid (IC50 = 1.20 and
1.20 ng mL1). These derivatives 40a and 40b (dose 3.16 and
10 mg kg1 day1) were also examined for their anti-malarial
activity against P. knowles in rhesus monkeys (Scheme 8)
of 7 days treatment using artesunic acid as standard drug
Scheme 5
Scheme 6
Scheme 7
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(dose 3.16 and 10 mg kg1 day1) and thus found to be better
than artesunic acid.
Recently, Singh et al. have synthesized24 a new series of
ether derivatives (41a–k) of dihydroartemisinin and their
antimalarial activity was evaluated against multidrug-resistant
P. yoelii nigeriensis in mice. The synthesis of the targeted
compounds was achieved through the Lewis acid catalyzed
(i.e. BF3Et2O) coupling reaction between dihydroartemisinin
9 with the corresponding alcohol in CH2Cl2 at subzero
temperature (10 1C to 5 1C) furnishing the corresponding
ether derivative in 65–99% yields as diastereomeric mixtures
of a and b-isomers, with the b-isomers as the major products
(Scheme 9). These new derivatives are highly lipophilic (logP
in the range of 5.51 to 7.19) as compared with b-arteether
(logP 3.84), and several of them are two- to four-fold more
active than b-arteether. Among, the ether derivatives, the
a-isomers are more active than the b-isomers. The a-ether
biphenyl derivatives 41f (logP= 6.91), and 41h (logP= 6.85)
are most active compounds of the series, provided 100%
protection to infected mice at 12 mg kg1  4 days as
compared to b-arteether, i.e. 100% and 20% protection at
48 mg kg1  4 days and 24 mg kg1  4 days, respectively.
More recently, Singh et al. have also synthesized25 a series
(42a–j) of ester derivatives starting from DHA 9, incorporating
pharmacologically privileged substructure, such as biphenyl,
admantane and ﬂuorene (Scheme 10) and evaluated for
antimalarial activity against multidrug-resistant (MDR)
P. yoeli nigeriensis by oral route. Several of these compounds
42a (logP = 6.95), 42b (logP = 6.89), 42c (logP = 6.53),
42d (logP= 6.53), 42e (logP= 6.05), 42f (logP= 5.99), 42g
(logP = 5.85), 42h (logP = 6.41), 42i (logP = 6.61), 42j
(logP = 6.79), were found to be more active than the
anti-malarial drugs b-arteether 12 (logP= 3.84) and artesunic
acid 13 (logP = 3.04). Compound 42i was found to be most
active of this series, providing 100% and 80% protection to
the infected mice at 24 mg kg1  4 days and 12 mg kg1 
4 days, respectively.
Although, the target for anti-malarial action of artemisinins
is controversial, recent evidence suggest that an Fe2+-activated
form of the drug potentially inhibits PfATP, a key parasite
Ca2+ transporter. On the other hand, the mode of action of
another anti-malarial drug quinine 1, has been suggested as a
result of interference with host hemoglobin digestion. Due to
anti-malarial synergism between artemisinin and quinine,
Walsh et al. have recently prepared26 a covalently linked novel
artemisinin–quinine hybrid compound 45 through the coupling
of dihydroartemisinin 9 with a carboxylic acid derivative of
quinine 44 via an ester linkage (Scheme 11). This hybrid
molecule had potent activity against the 3D7 and (drug-
resistant) FcB1 strains of P. falciparum in culture. The activity
of this hybrid molecule 45 (IC50 = 8.95 nM) was superior to
that of artemisinin 8 (IC50 = 49.4 nM) or, quinine 44 (IC50 =
149 nM) alone, or a 1 : 1 mixture of artemisinin and quinine.
Hybrid molecules (known as reversed chloroquine) of
chloroquine was earlier made by Peyton et al. and found to
be eﬀective against chloroquine resistant parasites.
(B) C-12 sulfur derivatives
Angiogenesis, the formation of new blood vessels from existing
host capillaries stimulated by biochemical stimulators, in
normal vascular systems is involved in wound healing,
embryonic development, and the female reproductive cycle
under elaborate regulations. In particular, tumor angiogenesis
is caused by angiogenic inducers playing a key role in the
growth of the solid tumors, their invasion, and metastasis.
Therefore, the control of angiogenesis may be a promising
therapeutic strategy for the related disease. Strategies for
regulating angiogenesis have been carried out mainly in molecular
biology. However, in spite of the settlement of bioavailability,
biostability, and eﬀectiveness, it has been insuﬃciently carried
out to develop small molecule anti-angiogenic agents. Therefore,
it is important to discover anti-angiogenic small molecules that
might be suitable as clinical therapies.
Scheme 8
Scheme 9
Scheme 10
Scheme 11
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Recently, Chen et al. have reported27 that artemisinin and
dihydroartemisinin and C-12 acetal type of artemisinin
derivatives display anti-angiogenic-activity. Consequently,
Oh et al. have synthesized28 C-12 sulfur derivatives of artemisinin
(46–52) starting from dihydroartemisinin 9 (Scheme 12) and
tested against HUVEC proliferation at the concentration level
of 1 mMusing artemisinin 8, and DHA 9. Compounds 46 (IC50=
0.93 mM), 52 (IC50 = 1.74 mM), and 51 (IC50 = 1.29 mM),
have displayed potent growth inhibitory activity as compared
to 8 (IC50 4 50 mM), and 9 (IC50 = 8.91 mM).
(C) C-12 carbon analogues
The poor bioavailability and rapid clearance observed with
ﬁrst-generation analogues of DHA is due to the acetal function
present in these derivatives. As discussed earlier in this article,
one of the principle routes of metabolism of artemether, for
example, involves oxidative dealkylation to DHA 9, a compound
associated with toxicity and short half life (Scheme 1).
Replacement of the oxygen at the C-12 position with carbon
would be expected to produce compounds not only with
greater hydrolytic stability but also with a longer half life
and potentially lower toxicity. Consequently, several groups
have developed synthetic and semisynthetic approaches to
C-12 carba-analogues.
O’Neill’s group has synthesized29 several novel second-
generation ﬂuorinated ether and ester analogues of arteether
and artemether and evaluated for their anti-malarial potency
(Scheme 13). All of their derivatives demonstrated high anti-
malarial potency in vitro against the chloroquine sensitive HB3
and resistant K1 strains of P. falciparum. The ﬂuorinated
aromatic ring systems selected were linked to alcohol 54 by
either an ester linkage, 56 or an ether linkage 55, starting from
the key intermediate allyl deoxo-derivative 53. In vitro, the
most potent derivative 55a (IC50 = 0.22) was 15 times more
active than artemisinin (IC50 = 3.04) and 5 times more potent
than DHA 9 (IC50 = 1.04) against HB3 strain of P. falciparum.
However, in vitro against P. berghei in the mouse, selected
derivatives were generally less potent than DHA 9 (ED50 =
1.15) with ED50 values between 5 to 8 mg kg
1. On the basis of
the products obtained from the in vitro biomimetic Fe(II)-
mediated decomposition of 55a, they believe that the radical
mediator of biological activity of this series may be diﬀerent
from that of the parent drug artemisinin 8.
Latter, Ziﬀer’s group has synthesized30 another series of
C-12 carba analogues (58a–60 and 61) using key intermediate
aldehyde 57, prepared through the O’Neill’s compound 53
(Scheme 14). The aldehyde 57 was then reacted with a variety
of Grignard reagents to produce 58a–d. These Grignard
products (58a–d) were oxidized to their corresponding ketones
(61) using Jones’ reagent. Aldehyde 57 was also reacted with a
Wittig reagent to aﬀord 59. They observed that the peroxide
moiety essential for anti-malarial activity was not altered
under the reaction conditions of the Wittig or Grignard
reactions. The reaction of 57 with trimethyl(triﬂuoromethyl)-
silane yielded a pair of isomeric alcohols 60a and 60b.
The in vitro anti-malarial activities of all the synthesized
compounds (58a–d, 59, 60, and 61) were determined against
two drug resistant clones (W-2 is chloroquine resistant,
meﬂoquine sensitive while D-6 is meﬂoquine resistant and
chloroquine sensitive) of P. falciparum. Out of all the synthesized
compounds tested, compounds 58bb (IC50 = 4.8 and 5.8) and
58db (IC50 = 5.4 and 6.8) were 5–7 times more potent than
artemisinin 8.
Scheme 12
Scheme 13
Scheme 14
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Posner et al. reported31 a series of C-12 carba analogues by
treating organometallic reagents with aldehyde 62 under con-
trolled conditions (Scheme 15). Treatment of aldehyde 62 with
organometallic reagents produces the allylic alcohol 63 while
aldehyde 62 reacts with Wittig reagent to form a mixture of
geometric isomers of exocyclic alkene 65 without cleaving the
endoperoxide linkage. Anti-malarial testing of these analogues
in vitro against P. falciparum NF54 malaria parasites, showed
that C-9,10 unsaturated, C-10 carbon substituted heteroaryl
artemisinin analogues ketones 64 (IC50 = 4.3 nM where
R = n-Bu and 4.6 nM where R = Ph), tertiary alcohol 66
(IC50 = 4.5 nM) and exocyclic alkene 65 [IC50 = 28 nM
(R = CHQCH2), 16 nM (R = (E)-CHQCHPh), 8.1 nM
(R = (Z)-CHQCHPh), 11 (R = (E)-CHQCHPhNO2-p)] are
all similar to clinically used natural artemisinin (IC50 = 10.1
1.3 nM) analogues.
It is generally accepted now that the carbon centered free
radicals generated in the course of degradation-rearrangement
of artemisinin and the like may play a major role in the
killing of malaria parasites. Thus, Wu et al.32 have reported
their ﬁndings on the Fe(II) induced cleavage of the peroxide
bond in artemisinin and its derivatives and the DNA damage
associated with this process. In order to aﬀord a sounder basis
for probing the chemical and biochemical processes that
artemisinin derived compounds may participate in, they
designed a few C-12 carba-derivatives that carry a UV
chromophore through a C–C s bond (Scheme 16). The
isomer 68 which has the normal conﬁguration (i.e. the same
conﬁguration as in artemisinin) at C-12 showed high
anti-malarial activity in the preliminary in vivo test on mice
against P. berghei IC173 strain. The abnormal isomer 69
(ED50 = 7.08 mg kg
1, ED90 = 60.99 mg kg
1) is obviously
much less potent than 68 (ED50 = 0.58 mg kg
1, ED90 =
1.73 mg kg1) against P. berghei K173 strain administered
orally to mice as suspensions in Tween 80 as compared to
artemether 10 (ED50 = 1.00 mg kg
1, ED90 = 3.10 mg kg
1).
The marked diﬀerence in the anti-malarial potencies of 68 and
69, due to their diﬀerence in stereochemistry only at C-12 in
the structures, has been claimed by these workers as an entirely
new observation and according to them the ease with which
the peroxide bond is cleaved may directly be related to the
anti-malarial potency of trioxane.
Recently, Khac et al. have reported33 the synthesis of C-12
amino and ester/acid analogues using Ziﬀer’s key intermediate
aldehyde 57 (Scheme 17). The key intermediate 57 was subjected
to condensation with a variety of aliphatic, substituted aromatic
and substituted heterocyclic amines to aﬀord the corresponding
Schiﬀ base derivatives, which upon borohydride reduction
aﬀorded corresponding C-12 amine derivatives 70a–d. For
the synthesis of C-12 esters/acid derivatives, aldehyde 57 was
reduced to alcohol, and further treated with a variety of
carboxylic acid anhydrides aﬀording the corresponding ester/
acid derivative 71a–c. Among the synthesized compounds, 71a
(IC50 = 0.4 and 0.5 nM), 71b (IC50 = 0.4 and 0.5 nM),
and 71c (IC50 = 0.4 and 0.5 nM) have shown very strong
anti-malarial potency against strains (W-2 and Ghana) of
P. falciparum. These compounds (71a, 71b, 71c) are about
25 times more potent to the resistant clone (W-2) and 20 times
to the sensitive clone (Ghana) than artemisinin (IC50 = 10 and
9 nM). In addition, other derivatives containing amino-alkyl
and heterocycles were also highly potent against P. falciparum.
Compound 70d (IC50 = 1.0 and 1.0 nM) is about 10 times
more potent than artemisinin.
Recently, Magueur et al. have reported34 that introduction
of gem-diﬂuoromethylene group at the C-12 position of the
artemisinin resulted in better in vitro antimalarial activity. They
Scheme 15
Scheme 16
Scheme 17
This journal is c The Royal Society of Chemistry 2010 Chem. Soc. Rev., 2010, 39, 435–454 | 443
have synthesized gem-diﬂuoromethylene deoxo-artemisinin 72
through artemisinin 8 in three steps (Scheme 18). The in vitro
antimalarial activity of artemisinin 8 (IC50 = 8.9) and
of compound 72 (IC50 = 4.6) were determined using the
chloroquine resistant FCB1 strain of P. falciparum.
(D) C-13 substituted derivatives from artemisitene
The majority of derivatives of artemisinin prepared so far were
derivatized through C-12 either as acetal and non-acetal
type, and only a few C-13 derivatives were reported.35
Artemisitene 73 exists in the same plant in much lower
yield and has less anti-malarial activity than artemisinin 8.36
However, artemisitene 73 can be easily prepared from
artemisinin 8 in a single-step reaction in 73% yield. It contains
an a,b-unsaturated lactone moiety, which can be used
as a Michael receptor for derivatization. Thus, Li et al.
prepared37 74a–c and 75a–c with 1,2,4-triazole, benzotriazole
or benzamidazole moiety under diﬀerent conditions
(Scheme 19), heating 1,2,4-triazole as its salts and artemisitene
73 in CH3CN at 60 1C gave a mixture of 74a and 75a
(40% yield), reﬂuxing benzotriazole and artemisitene 73 in
aqueous ethanol gave 74b and 75b (40 and 29% yield),
reacting benzimidazole and artemisitene 73 in THF in
the presence of KF-Al2O3 gave 74c and 75c (26 and 38%
yield). In in vivo anti-malarial tests against K173 strain of
P. berghei, the mixture of 74a and 75a showed nine times
(SD50 = 2.38 mg kg
1 day1, SD90 = 6.52 mg kg
1 day1)
more potency than artemisinin 8 (SD50 = 5.13 mg kg
1 day1,
SD90 = 11.50 mg kg
1 day1). Compound 74b (SD50 =
5.48 mg kg1 day1, SD90 = 11.41 mg kg
1 day1)
showed activity comparable to that of the artemisinin 8.
Compound 74c (SD50 = 3.94 mg kg
1 day1, SD90 =
10.05 mg kg1 day1) and 75c (SD50 = 1.59 mg kg
1 day1,
SD90 = 56.03 mg kg
1 day1) were more active than
artemisinin 8. Compound 74c had higher activity than its
isomer 75c.
(E) Artemisinin dimers, trimers and tetramers: novel leads in
drug discovery
It has been established through the structure–activity relation-
ship (SAR) studies of artemisinin and its various kinds of
C-12/C-13 ether/ester derivatives that only peroxide-linkage
aﬀects the anti-malarial and anti-cancer activity. Furthermore,
several drawbacks associated with these compounds viz
solubility, thermal and hydrolytic stability, bioavailability,
and short half life etc, have led to development of second
generation C-12/C-13 trioxane-derivatives. Furthermore, it
was thought worthwhile that the extent of anti-malarial
activity depends upon the extent of the number of peroxide
units, which can be increased by adding of additional artemisinin
moiety through careful chemical manipulations. Thus, researchers
have directed their eﬀorts for the synthesis of various kinds of
artemisinin dimers, trimers and tetramers of various length
and ﬂexibility. Artemisinin dimers reported till date, have
displayed structural diversity, separated through artemisinin
monomer units with or without linkers of various length and
ﬂexibility with diverse stereochemistry. Several of these C-12/
C-13 carbon artemisinin dimers have shown outstanding
anti-malarial and anti-cancer activity and are better than
C-12 ether/ester dimers. Artemisinin trimers and tetramers
of C-12/C-13 non-acetal derivatives have also been reported in
recent years, wherein artemisinin units are connected through
linkers of various kinds with diverse length and stereochemistry.
However, the number of artemisinin dimers synthesized so
far is far-ahead of the number of artemisinin trimers and
tetramers. Many of these dimers, trimers and tetramers have
shown outstanding anti-malarial and anti-cancer activities
compared to artemisinin and related compounds, and are
in various phases of clinical trials. These compounds may
become future potential leads in anti-malarial and anti-cancer
chemotherapy.
I. Artemisinin dimers
Based on the C-12/C-13 linkage between artemisinin units
through the linker, whether acetal or non-acetal, artemisinin
dimers have been classiﬁed as follows:
(a) C-12 oxa dimers: Wherein two artemisinin monomers
units are linked through the C-12 acetal (i.e. ether–ester
linkage) linker.
(b) C-12 carba dimers: Wherein two artemisinin monomers
units are linked through the C-12 non-acetal (i.e. carbon–
carbon linkage) linker.
Scheme 18
Scheme 19
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(c) C-13 carba dimers: Wherein two artemisinin monomers
units are linked through the C-13 non-acetal (i.e. carbon–
carbon linkage) linker.
(a) C-12 oxa dimers. In search for new potential artemisinin
derivatives, several new C-12 oxygen derivatives have been
reported by various groups. Thus, Beekman et al. have
reported38 the anti-cancer activity of C-12 oxa-dimers where
two artemisinin units were connected through an ether-linkage
(Scheme 20). The cytotoxicity of these derivatives were determined
against EN2 tumor cells using the MTT assay. They realized
that artemisinin 8 (IC50 = 0.98) was more cytotoxic than the
corresponding deoxyartemisinin 76 (IC50 = 111), which
lacks an endo-peroxide linkage. Ether–linked dimers of
deoxyartemisinin with deﬁned stereochemistry were found to
diﬀer in extent of cytotoxic eﬀect on EN2 cells. The
non-symmetrical dimer 77 (IC50 = 0.11) was more cytotoxic
than the symmetrical dimer 78 (IC50 = 2.0). Similarly, the
symmetrical dimer 80 (IC50 = 99.8) was less eﬀective than 79
(IC50 = 8.9).
In order to study the role of linker in aﬀecting the biological
activity of dimers, Posner et al. have synthesized39 a series of
artemisinin C-12 oxa dimers linked through two artemisinin
units either by a polyethylene glycol or carbon chain link
or disulﬁde linker, with varying length and ﬂexibility
(Scheme 21). The syntheses of targeted dimers were achieved
starting from dihydroartemisinin 9 using the required linker.
They have tested the anti-proliferative activities in normal
murine keratinocytes using calcitriol as a standard drug and
anti-tumor activity in various cancer cells in vitro. Of the
dihydroartemisinin polyethylene-glycol dimers 81a–c, the one
with b-stereochemistry at both of the lactol acetal positions
(i.e. 81b, IC50 = 1.9 nM) is more active than artemisinin 8
(IC50 = 10 nM). Likewise, the b,b-dimers 81d and 81e are
highly antiproliferative.
Recently, Grellepois et al. have synthesized40 another C-12
oxa dimer 82 through oleﬁnic metathesis reaction using
compound 20 (Scheme 22). Preliminary growth inhibitory
activities were evaluated in vitro using a diverse panel of
60 human cancer cell lines. This dimer 82 was eﬃcient in
cancer cell growth inhibition with a GI50 less than 10 nM. In
particular, TGI (total growth inhibition) data shows the
selectivity and potency of dimer 82 against a few cancer cell
lines (e.g. leukemia, HL-60, non-small cell lung cancer
NCI-H226, colon cancer COLO 205, and KM-12, CNS cancer
SF-295).
(b) C-12 carba dimers. Although C-12 oxa dimers have
displayed high antimalarial, antiproliferative and anti-tumor
activities in vitro, often they are hydrolytically unstable. In
order to enhance the hydrolytic stability, researchers have
directed their eﬀorts to synthesize a variety of C-12 oleﬁnic
carba dimers. Thus, Posner et al. have ﬁrst reported41 syntheses
of C-12 oleﬁnic carba dimers of m-xylene by reacting their
previously prepared aldehyde 62, with Wittig reagent 83 to
aﬀord three isomers with diﬀerent stereochemistry 84a–c
(Scheme 23). The in vitro anti-malarial potencies of m-xylene
dimers 84a–c against chloroquine sensitive P. falciparum
(NF54) parasites was measured, wherein 84a (IC50 = 77 nM),
84b (IC50 = 35 nM), 84c (C50 = 18 nM) were found less
potent than artemisinin 8 (IC50 = 9.7 nM). They have further
extended the study and synthesized C-12 non-acetal saturated
dimers 85a.b starting from artemether 10 via novel titanium-
promoted condensation (Scheme 24). They have further
synthesized the C-12-non-acetal saturated C-12 dimers
(87–89) by coupling of recently prepared artemisinin derived
ﬂuoride 86 via Friedel–Crafts or aluminium acetylide
condensations (Scheme 25). Although benzoylmethylene
dimers 85a and 85b and acetylenic dimers 89a and 89b are
stereochemically b-linked to C-12 of the artemisinin, aryl
dimers 87 and 88 are a-linked; the basis for this diﬀerence in
stereochemistry of attachment is not fully understood. Unlike
the bis-acetylene dimers 89a and 89b, aryl dimer 87 and furan
dimer 88 are considerably more potent anti-malarial agents
(IC50 = 1.3–3.2 nM) than natural artemisinin (IC50 = 9.7 nM)
as mentioned in Table 2. Compounds 85a–c, 87, 88, 89a–c
showed good to excellent antiproliferative activity. Dimers
85a, 87 and 89a were specially potent and selective in
Scheme 20
Scheme 21
Scheme 22
This journal is c The Royal Society of Chemistry 2010 Chem. Soc. Rev., 2010, 39, 435–454 | 445
inhibition of growth of some human cancer cell lines in the
NCI in vitro 60-cell line assay.
Later on, Posner’s group has also synthesized42 C-12 non-
acetal dimers 90a–c starting from dihyroartemisinin acetate 29
and their ketone functionality was converted into diﬂuoro
derivative 91a.b using bis(2-methoxyethyl)amino sulfur triﬂuoride
(BAST) (Scheme 26). The peroxide group of C-12 90a dimer
was reduced using Zn/AcOH to aﬀord 92. Anti-malarial
activity of these compounds were tested against chloroquine-
sensitive NF54 strain of P. falciparum. Dicarbonyl dimers
90a–c are 2–5 times more potent (90a, IC50 = 1.9 nM; 90b,
IC50 = 1.7 nM; 90c, IC50 = 3.9 nM) than artemisinin 8
(IC50 = 7.6 nM), whereas tetraﬂuorinated dimers 91a–b are
2-4 times less potent (91a, IC50 = 28 nM; 91b, IC50 = 15 nM)
than artemisinin 8. Dimer 92 (IC50 = 1030 nM) without
peroxide linkage posseses very weak or no antimalarial activity.
Antiproliferative activities were measured in vitro using
murine keratinocytes for new non-ﬂuorinated dimers 90b
and 90c and for new ﬂuorinated dimers 91a and 91b. It is
noteworthy that these dimers are more eﬀective at 1 mM
concentration than calcitriol used as a standard drug. Growth
inhibitory activities at nanomolar to micromolar concentrations,
measured in vitro using a diverse panel of 60 human cancer cell
lines, indicates that non-ﬂuorinated dimers 90b and 90c are
particularly inhibitory to leukemia cells, and these dimers are
very selectively potent in a few other cancer cell lines (e.g.
colon 205, ovarian cancer OVCAR-4, non-small cell lung
EKVX). The highly selective and powerful anticancer activities
of dimers 90b and 90c, coupled with lack of cytotoxicity, make
these promising lead compounds for further preclinical study
in dual action chemotherapy of both malaria and cancer.
Later on, Jung et al. reported43 a series of C-12 non-acetal
amido (97a–b, 100, 101) and sulﬁde/sulfoxide (102, 103, 104,
105) dimers (Scheme 27). Synthesis of target compounds were
achieved from the key intermediates 94 and 96, which were
easily synthesized from compound 93. The syntheses of 97a,b
were achieved through the direct coupling of acid 94 with
amino compound 96 using EDC–HOBt system. Synthesis of
dimers 100 and 101 was achieved by coupling of compound
96a with protected glutarate 98 using the EDC–HOBt system
to aﬀord compound 99, which upon further coupling with 96a
using EDC–HOBt aﬀorded t-Boc protected amido-dimer
100. Compound 100 upon treatment with TFA aﬀorded
Scheme 23
Scheme 24
Scheme 25
Table 2 Antimalarial activity of C-12 deoxyartemisinin dimers 85–89
Dimer Linker
Antimalarial activity,
IC50/nM
85a 1.9
85b 1.9
87 1.3
88 3.2
89a 30
89b 36
8 9.7  1.8
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unprotected amido dimer 101. Compound 95a on treatment
with Na2S aﬀorded compound 102which upon further treatment
with m-CPBA aﬀorded compound 103. Compound 95a on
treatment with 1,3-thiol aﬀorded dimer 104, which upon
further treatment with m-CPBA aﬀorded compound 105.
The in vitro cytotoxicity of artemisinin and related dimers
against murine and human cancer cells. Sulﬁde dimer 102
(IC50 = 0.40 mg mL
1) is active comparable to aldriamycin
(IC50 = 0.39 mg mL
1) and four times more active than
mitomycin (IC50 = 1.50 mg mL
1) against-mouse ﬁbroblast
leukemia (P388). Sulfone-linked dimer 103 (IC50= 1.04 mgmL
1)
is active comparable to mitomycin (IC50 = 0.85 mg mL
1) and
six times more active than adriamycin (IC50 = 6.24 mg mL
1)
and taxol (IC50 = 7.39 mg mL
1) against human placental
choricarcinoma cells (Bewo). Dimer 97a (IC50 = 0.005 mg mL
1),
particularly, is 24 times more active than aldriamycin
(IC50 = 0.12 mg mL
1) and 200 times more active than
mitomycin (IC50 = 0.93 mg mL
1), but 50 times less active
than taxol (IC50 = 0.0001 mg mL
1).
Later on, Posner’s group has synthesized44 a series of
artemisinin dimers (106–118) starting from dihydroartemisinin
acetate 29 (Scheme 28). Compound 29 upon treatment with
allylic bis-silane using tin chloride aﬀorded dimer 106, which
was used as a key intermediate for the transformation to a
diverse series of dimer derivatives (107–116). Anti-malarial
activity of these dimer derivatives were carried out in vitro
using chloroquine-sensitive P. falciparum (NF 54) parasites. In
sharp contrast to the potencies of the natural trioxane
artemisinin 8 (IC50 = 9.0 nM) and of the initial oleﬁnic dimer
106 (IC50 = 24 nM), alcohol and diol dimers 107 (IC50 =
0.87 nM) and 110 (IC50 = 0.59 nM) and ketone dimer 112
(IC50 = 0.91 nM), all have substantially enhanced potencies,
with IC50 values below 1 nM. Also, water-soluble carboxylic
acid dimers 108 (IC50 = 2.0 nM), 109 (IC50 = 1.7 nM), 111
(IC50= 3.0 nM), 114 (IC50 = 2.1 nM), and 118 (IC50 = 2.4 nM)
all are several times more potent than artemisinin 8. Anti-cancer
growth inhibitory activities of these dimers were measured
in vitro using a diverse panel of human cancer cell lines,
indicates that alcohol and diol dimers 107 and 110 are strongly
growth inhibitory but not cytotoxic towards several human
cancer cell lines. Moreover, water-soluble dimers 108, 111 and
Scheme 26
Scheme 27
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118 are also potent inhibitors of cancer cell growth without
being cytotoxic. These semi-synthetic new chemical entities
107 and 110, and especially the easily synthesized dimer
carboxylic acids, 108 and 111, therefore, deserve further
preclinical evaluation as potential drug candidates for chemo-
therapy of malaria and cancer.
Later on, Posner and O’Neill’s group synthesized45 a new
series of artemisinin dimers (119, 121–123) starting from their
previously prepared key intermediate 54 (Scheme 29). All
of these dimers prepared displayed potent low nanomolar
anti-malarial activity vs. the K1 and HB3 strains of
P. falciparum. The most potent compound assayed was
phosphate dimer 122a (IC50 = 0.2 nM), which was greater
than 50 times more potent than the parent drug artemisinin 8
(IC50 = 12.3 nM), and about 15 times more potent than
the clinically used acetal artemether 10. All of the dimers
expressed poor anticancer activity apart from the trioxane
phosphate ester dimer 122a and 122b, which expressed nano-
molar growth inhibitory (GI50) values vs. a range of cancer cell
lines in the NCI 60 human cell line screen. Furthermore,
detailed studies on these dimers in vitro in HL60 cells demonstrate
that both phosphate ester dimers 122a (IC50 = 0.14 mM) and
122b (IC50 = 0.24 mM) are more potent than the anti-cancer
agent doxorubicin (IC50 = 0.51 mM).
Posner’s group has further synthesized46 isobutyric acid
dimer 124 and isonicotinate N-oxide 125 dimer starting from
alcohol dimer 107 (Scheme 30). Antimalarial potencies of
dimer 124 and 125 against chloroquine-sensitive P. falciparum
(NF 54) parasites were determined. Both isonicotinateN-oxide
dimer 125 (ED50 = 0.53 nM) and isobutyric acid dimer 124
(ED50 = 2.4 nM) were considerably more antimalarially
eﬃcacious than clinically used sodium artesunate 12 (ED50 =
1.5 nM) via both oral and intravenous administration. Both
alcohol dimer 107 and N-oxide dimer 125, but not carboxylic
acid dimer 124, very strongly inhibit the growth of prostate
cancer cells.
Recently, Posner et al. have also reported47 the syntheses of
another new series of artemisinin bis-benzylic dimers
(127–131) starting from conjugated dimer 126, obtained
directly from dihydro-artemisinin acetate 29 (Scheme 31).
Thus, conjugated new dimer 126 undergoes 4 + 2-cycloaddition
reaction to aﬀord compound 127. Dimer 127 through a series
Scheme 28
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of other synthetic-transformations aﬀords dimer 128–131.
Anti-malarial activities of these dimers (126–131) were determined
in vitro against chloroquine-sensitive P. falciparum (NF 54)
parasites. Except for the water-soluble phthalic acid dimer 128
(IC50 = 360 nM), all of other dimers are considerably more
potent anti-malarials [(126, IC50= 2.9 nM), (127, IC50= 1.6 nM),
(129, IC50 = 0.77 nM), (130, IC50 = 3.0 nM), (131, IC50 =
3.7 nM)] than artemisinin 8 (IC50 = 6.6 nM).
Preliminary growth inhibitory activities at nanomolar to
micromolar concentrations were measured in vitro using a
diverse panel of 60 human cancer cell lines. It has been realized
that trioxane phthalate dimer 127 (IC50 = 500 nM) is
approximately 10–20 times more potent than trioxane-monomer
DHA 9 and that trioxane diol dimer 129 (IC50 = 46.5 nM)
is approximately 110–220 times more potent than DHA 9,
without being toxic to primary normal cervical cells. The most
potent and selective two dimers 127 and 129 deserve further
preclinical evaluation as potential drug candidates for eﬀective
chemotherapy of malaria and cancer.
Later on, Posner’s group synthesized48 C-12 dimers
(132–134) starting from his previously reported alcohol dimer
107 (Scheme 32). The mechanism of action of these dimers
were examined in human (LNCaP) and mouse (TRAMP-C1A
Scheme 29
Scheme 31
Scheme 30
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and -C2H) prostate cancer cell lines. All these dimers
(132–134) inhibited cell growth with the 134 being most potent
in C1A (GI50 = 18.0 nM), C2H (GI50 = 17 nM) and LNCaP
(GI50 = 17.9 nM) cells in comparison to the standard drug
doxorubicin (GI50 = 45.3 nM). These trioxane dimers induced
G0/G1 cell cycle arrest in LNCaP cells and decreased cells in S
phase. These changes correlated with modulation of G1 phase
cycle proteins, including decreased cyclin D1, cyclin E and
cdk2, and increased P21waﬂ and p27kipl. These dimers
(132–134) also promoted apoptosis in LNcaP cells with
increased expression of proapoptotic BAX. These results
demonstrate that these dimers (132–134) are potentially useful
agents that warrant further preclinical development for the
treatment of prostate cancer.
Simultaneously, Jung et al. have also reported49 a new series
of trioxane–artemisinin dimers (136, 137) starting from their
previously prepared key intermediate alcohol 135. Thus, the
alcohol 135 was ﬁrst converted into a malonate dimer 136,
obtained by treatment of alcohol 135 with malonyl chloride.
This malonate dimer 136 was further converted to Bingel
adduct trioxane dimer 137 (i.e. fullerene conjugate dimer) by
treatment with fullerene C60 (Scheme 33). They have tested the
in vivo antiangiogenesis activity of these dimers (136, 137)
along with the standard drug fumagillin, thalidomide and
artemisisinin 8. It has been realized that the anti-angiogenic
eﬀect of fullerene dimer 137 is similar to fumagillin and
thalidomide and double in comparison with artemisinin 8.
Recently, Posner’s group has synthesized50 another new
series of trioxane dimers (138–140) starting from their
previously prepared dimer compounds 106, 107, 110, 124 as
mentioned in references (Scheme 34). Four of these dimers
(134, 138, 139, 140a) cure malaria-infected mice after only a
single subcutaneous dose, and two other dimers (140b, 140c)
cure after three oral doses in P. Berghei infected mice. These
dimer compounds have become lead drug candidates to enter
in advanced preclinical evaluation and would ultimately be
used in human studies.
More recently, Posner’s group has also reported51 another
series of trioxane dimers (141–163) starting from their
previously reported dimers 106, 107, 110, 112, 124 as a key
intermediates (Scheme 35). Thus, hydrazone dimer 141 was
obtained from the corresponding keto-compound 112, ketal
dimers (142–149) were synthesized from the diol dimer 110,
various alkylated ether/esters dimers (150, 152) were synthesized
by selective alkylation of diol dimer 110, various amide dimers
were synthesized (156–161), and oxadiazoles dimers (162, 163)
from the corresponding acid dimer 124, which was obtained
through the oxidation of alcohol dimer 107. This alcohol
dimer 107 was further converted to trioxane dimers
(153–155). Out of 23 dimers synthesized, 11 of these new
trioxane dimers (142–145, 147–150, 153, 155 and 156) cure
malaria-infected mice via oral dosing at 3  30 mg kg1. These
trioxane dimers are stable both thermally and hydrolytically.
Furthermore, chemical structure–biological activity relationship
(SAR) is ongoing, aimed at developing trioxane dimers able to
achieve single oral dose cure.
(c) C-13 carba dimers. In order to search for more hydro-
lytically stable and potent compounds, researchers became
interested to synthesize the C-13 dimers of artemisinin 8,
starting from the key intermediate artemistine 73.
Ekthawatchai et al. have reported52 synthesis of C-13
carba-dimers (164, 166–168) starting from the key intermediate
artemisitene 73 (Scheme 36). The synthesis of dimers 164a–d
was achieved through the base-catalyzed coupling of 73 with
the disulﬁde linkers of diﬀerent length. However, compounds
164a–d were not found to be very stable and spontaneously
decomposed in solutions or upon storage at room temperature
giving complex mixtures. Synthesis of C-13 dimers 167 and
168 was achieved through Grignard reagent of suitable length
with the key intermediate 73. Dimer 166 was achieved through
the nucleophilic addition of 165 with 73. Anti-malarial activities
of dimers 164a–d, 167 and 168 were tested in an in vitro
malaria screening system against P. falciparum (K1, multidrug
Scheme 32
Scheme 33
Scheme 34
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resistant strain). It has been observed that these dimers
(164a–d, 167 and 168) do not show promising anti-malarial
activity, perhaps since the stereochemical orientations at C-13
and C-130 of the two artemisinin molecules in these dimers
might play almost insigniﬁcant roles with regard to their
biological activities. Anticancer activities of artemisinin dimers
166a–g show high potency against vero cells only.
Recently, Grellepois et al. have reported40 synthesis of C-13
carba dimer 170 (Scheme 37) starting from C-13 allylic ether
compound 169 using Grubbs metathesis reaction. They have
further synthesized C-13 oleﬁnic dimer containing hydroxy
groups 172 through a metathesis approach, starting from C-13
allylic alcohol 171.
Preliminary growth-inhibitory activity of these dimers (170,
172) was evaluated in vitro using a diverse panel of 60 human
cancer cell lines. Compound 170 was eﬃcient in cancer cell
growth inhibition with a GI50 less than 10 nM in many cases.
Particularly, TGI data shows the selectivity and potency of
dimer 170 against a few cancer cell lines (e.g. leukemia HL-60,
non-small cell lung cancer NCI-H-226, colon cancer COLO
205, and KM-12, CNS cancer SF-295).
(II) Artemisinin trimers and tetramers
In order to search for more potent, more bioavailable, hydro-
lytically stable, and less toxic compounds of artemisinin
derivatives, researchers have directed their eﬀorts towards
the synthesis of trimer and tetramer derivatives of artemisinin.
Ekthawatchai et al. have ﬁrst reported52 synthesis of trimers
173a,b and tetramers 174a,b of artemisinin, starting from their
own key intermediate artemisitene 73 (Scheme 38). Anti-
malarial activities of these trimers [(173a, EC50 = 2.4 nM),
(173b, EC50 = 3.1 nM)] and tetramers [(174a, EC50 = 5.8 nM),
(174b, EC50 = 20 nM)] are quite impressive and higher (except
174b) in comparison to artemisinin 8 (EC50 = 12.1 nM).
Later on, Jung et al. synthesized43 another artemisinin
trimer 175 through the coupling of their previously synthesized
key intermediates 94 and 96a (Scheme 39). The in vitro
cytotoxicity of this trimer 175 was tested against murine and
human cancer cells. The trimer 175 (IC50 = 0.12 mg mL
1)
is three times more active than adriamycin (IC50 =
0.39 mg mL1), 12 times more active than mitomycin
((IC50 = 1.50 mg mL
1), and 20 times more active than taxol
(IC50 = 2.27 mg mL
1) against P388. Furthermore, it has been
realized by these researchers that this trimer 175 is most potent
in almost all the human cancer cell lines tested, and should
receive more attention as a possible anti-cancer drug candidate.
Mechanism of action of artemisinins
(A) Mode of anti-malarial activity
The entry of the malaria parasites into their human host is
through a mosquito bite. They ﬁrst enter the liver and replicate
there for two weeks, before beginning a cycle of red blood cell
invasion, followed by growth, replication and red cell destruction
that leads to the symptoms of the disease. The artemisinin
drugs are known to act speciﬁcally during this blood stage.
Although the mechanism of action of artemisinins is still not
conclusive, there are strong evidences to suggest that an
Scheme 35
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endoperoxide linkage of artemisinins and a heme iron play
critical roles in their mechanism of action, which is comprised
of two distinct steps.53 In the ﬁrst step (activation step), the
heme iron attacks and breaks the endoperoxide linkage of
artemisinin to produce an oxy free radical, which is then
rearranged to give a carbon free radical. In the second step,
the carbon free radical produced from the ﬁrst step will
alkylate speciﬁc malarial proteins causing lethal damage to
malarial parasites (Scheme 40).
For the activation step, there are two possible pathways
1 and 2 (Scheme 40). In pathway 1, the heme iron attacks the
Scheme 36
Scheme 38
Scheme 37
Scheme 39
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endoperoxide moiety at the O2 position, giving the free radical
at the O1 position (176). This process is followed by an
intramolecular 1,5-H shift and the C4 free radical (178) is
obtained. In pathway 2, the heme iron, on the other hand,
attacks the endoperoxide moiety at the O1 position, giving the
free radical at the O2 position (177). This process is followed
by a hemolytic cleavage of the C3–C4 bond, also resulting in
the C4 free radical (179). Hence, it could be concluded that the
C4 free radical product is very critical for antimalarial activity
of artemisinins.
(B) Mode of anti-cancer activity
In the mid-1990s selective cytotoxicity of artemisinin-derived
peroxides towards cancer cells also became known. Cancer
cells require much iron to assist their rapid proliferation and
indeed, human cancer cells are known to be richer than normal
human cells in receptors for transferrin, an iron transporting
protein. Most cancer cells express higher cell surface concen-
tration of transferrin receptors than normal cells and have
high rates of iron intake via transferring receptors. Eﬀorts to
explore the molecular mechanism of action of these monomeric
1,2,4-trioxanes towards tumor cells have established54 a
correlation between a trioxane’s potency and m-RNA gene
expression, cell doubling time and the portion of cells in
diﬀerent cell cycle phases. According to Moore and his
co-workers, a unique structure bearing endo-peroxide could
be a trigger for the generation of active oxygen radicals via
homolytic cleavage of the weak oxygen peroxide bond accelerated
by higher ferrous iron concentration of the cancer cells which
may cause selective and preferential damage to vital cellular
structure of the relatively active cancer cells. While the anticancer
mode of action of artemisinins is relatively little studied and
known, recent studies have revealed a radical alkylation and
inhibition of the G1 cycle for anticancer activity.
Conclusions
In this review, we have attempted to give a comprehensive
overview on the recent developments of artemisinin and its
derivatives as potential anti-malarial and anti-cancer agents.
Comparative anti-malarial and anticancer activities of these
derivatives were discussed and a study on the eﬀorts towards
the development of various artemisinin dimers, trimers and
tetramers as potential ‘leads’ for anti-malarial and anticancer
drugs have been carried out, where the activities have been
correlated with artemisinin and various other standard anti-
malarial and anti-cancer drugs. From the current degree of
development, it is understandable that several new potent
dimers and trimer ‘lead’ molecules have been discovered in
recent years which are in the various phases of clinical trials.
Such drug candidates include compounds 90b, 90c, 107, 110,
108, 111, 127, 129, 132–134, 138–140 and 175 as novel leads in
anti-malarial and anti-cancer drug discovery. In view of
development of new ‘lead’ compounds, it is hoped that interest
in this rapidly growing area will continue further to yield
exciting results in the coming years.
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